{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This equivalence-dose randomized controlled trial evaluated whether liposomal bupivacaine provides non-inferior analgesia to the standard combination when administered via rhomboid intercostal block (RIB)."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this double-blind randomized controlled trial, 90 VATS patients were randomly assigned to receive either..."
      },
      "Participants": {
        "score": 2,
        "evidence": "90 VATS patients were randomly assigned to receive either..."
      },
      "Intervention": {
        "score": 2,
        "evidence": "a 20-ml premixed solution containing 93 mg of liposomal bupivacaine combined with 25 mg of plain bupivacaine (liposomal bupivacaine group), or a 20-ml admixture of 105 mg of plain bupivacaine and 5 mg of dexamethasone (plain bupivacaine with dexamethasone group)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This equivalence-dose randomized controlled trial evaluated whether liposomal bupivacaine provides non-inferior analgesia to the standard combination when administered via rhomboid intercostal block (RIB)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome assessed was the area under the curve (AUC) of the 48-h resting pain numeric rating scale (NRS)."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "In this double-blind randomized controlled trial, 90 VATS patients were randomly assigned to receive either..."
      },
      "Blinding": {
        "score": 2,
        "evidence": "In this double-blind randomized controlled trial..."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "90 VATS patients were randomly assigned to receive either..."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Liposomal bupivacaine was shown to be non-inferior to plain bupivacaine with dexamethasone, with a 48-h NRS AUC of 105.5\u2009\u00b1\u200913.6 vs . 113.1\u2009\u00b1\u200916.3 (mean difference \u2212\u20097.6; 95% CI \u2212\u200913.9 to \u2212\u20091.2, upper limit\u2009<\u2009non-inferiority margin 3.7)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Safety profiles were comparable, with no between-group differences in postoperative nausea and vomiting or other severe complications ( P >\u20090.05)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered on ClinicalTrials.gov ( NCT06392191 )."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}